Issue Areas

Fostering Competitive Markets

Prescription drug prices continue to rise, threatening to make vital therapies unaffordable for many patients.

Learn more

Kaiser Permanente believes it is time for a new legal and policy landscape for drug pricing that rewards innovation and discovery, but also provides medicines at prices patients and the health care system can afford.

Featured content
Syringes With Needed
Biosimilars at Kaiser Permanente: Lessons in successfully reducing spending on prescription drugs
Prescription White Pills
Building a bigger table for a more equitable drug development system
The Medicaid Drug Rebate Program and the impact of “best price” rules
Capitol Dome
How to save the patent system in 3 easy steps
A Man Handing A Prescription To A Pharmacists
The price Is wrong: Why we need to curb prices on biologics to protect patients
Our thoughts on HHS’s blueprint to lower drug prices: It’s time for a new legal and policy landscape
Reflections on high drug pricing in America: Where we are and where we’re headed
Kaiser Permanente Institute For Health Policy Staff
A provider and payor’s perspective on drug pricing
Events
Pills
Building Racial Equity into the Drug Development System: Clinical Trials, Access, and Affordability
Kaiser Permananete Institute For Total Health Forums
Addressing High Drug Pricing